-
亞歷克斯・博迪獲任命為 SCANDIC FINANCE 集團副總裁
-
Алекса Боді призначено віцепрезидентом групи SCANDIC FINANCE
-
Алекс Боди назначен вице-президентом группы SCANDIC FINANCE
-
Alex Bodi appointed Vice President of SCANDIC FINANCE GROUP
-
Alex Bodi, numit vicepreședinte al grupului SCANDIC FINANCE
-
Yealink Summit Addresses AI Governance and Workplace Trust
-
Essential Baking Tools for Christmas Cookie Perfection
-
Elon Musk jokes about moving businesses to space after US midterms
-
West Mercia Police opens 2027 cadet applications to Worcestershire teenagers
-
NHS to test blood screening designed to detect 13 cancers earlier
-
Worcestershire road closures announced for Remembrance Sunday events
-
Democrats near House takeover as voters judge Trump presidency
-
UBC professor describes police call after Galloway remark as act of care
-
Lethbridge submits interest in provincial ground ambulance contract
-
False voting claims spread rapidly during US Election Day
-
The Cat in the Hat expands its stakes to cosmic scale in animated reboot
-
Lettermen co-founder Tony Butala dies at 87
-
Byron Donalds wins Florida governor race and underscores Republican strength
-
James Talarico defeats Ken Paxton in historic Texas Senate result
-
Physicist Claims Alberta Data Center Releases Energy of 23 Atomic Bombs Daily
-
Commentator predicts possible US strike on Iran as regional tensions rise
-
Goa plans relationship-readiness course amid concern over divorces
-
Jordan Bardella's Wealth and Financial Transparency Under Scrutiny
-
Manchester United climbs standings after 3-2 Champions League win over Roma
-
India introduces four-layer motor insurance choice from December 15
-
Mutual fund returns show shifting leaders across market-cap categories
-
DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
-
Sibannac CEO Exchanges Common Shares for Series D Preferred
-
BlueFuture Aquatics, Inc. (Formerly NaturalShrimp) Announces Support for the Administration's America First Seafood Strategy
-
Glo Tanning Opens in Tempe With Red Light Therapy, Skincare and More
-
Strategic Metals Ltd. Announces Acquisition of Control and Direction of Additional Securities of GGL Resources Corp.
-
Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 05
-
How to Make the Most of a Boat Rental Vacation
-
Best Rated Gold IRA Companies 2026 for US Consumers Rankings Released by Experts
-
Clarity Tax Relief Publishes Analysis of the 2025 IRS Data Book Collection Figures
-
Ryde Signs Strategic MOU with Dimension AI to Explore US$278 Million Three-Year GPU-as-a-Service Collaboration
-
Silver Storm to Present at the 2026 Precious Metals Summit Zurich Conference
-
Euro Stablecoins Added $263 Million in a Year, Up 54%, While Dollar Supply Fell, DIA Study Finds
-
Gold Terra Announces 6.61 g/t Gold over 7.35 Metres Including 31.6 g/t Gold over 1.1 Metres on the Campbell Shear Zone 103N Extension, Con Mine, Yellowknife, NWT
-
Cognitum One Unveils MetaLLM, Self-Improving Model Control Plane for AI Agent Swarms
-
FireFox Gold Drills 6.15m at 4.10 g/t Gold at Gabbro Target, Further Expanding Gold Footprint at Mustajärvi Project, Lapland, Finland
-
Quebec Selects NiobiumX's Shipshaw Carbonatite as One of Five for Detailed Study; NiobiumX Announces Private Placement of Flow-Through Units
-
U.S. Navy Contracts with CORAS.ai to Advance Program Execution, Readiness, and Decision Intelligence
-
BHEL wins Adani Power projects valued at up to ₹28,000 crore
-
IndiGo holds talks with Embraer over potential order for 100 aircraft
-
India seeks threefold increase in coal stocks to prevent summer power shortages
-
Indian companies report mixed second-quarter results on November 4
-
Indus Towers expands solar-powered network to 50,000 telecom sites
-
KKR secures Indian regulator approval for Gentari Renewables investment
Chinese take risks on black market drugs as Covid surges
Desperate families searching for critical Covid-19 medication in China, faced with bare pharmacy shelves and an explosion of cases, are being driven into murky online marketplaces rife with price gouging and fraud.
Beijing last month abruptly tore down its hallmark zero-Covid virus containment policy, lifting widespread restrictions that had triggered nationwide protests and stifled the economy. The move unleashed a torrent of infections across the country.
The current Covid wave has seen drug stores stripped of supplies, as people snap up cold and fever treatments. Many have been forced to turn to sketchy online sellers with little guarantee of getting what they have paid for.
China's people have long endured scandals involving tainted medicine, fabricated clinical trials and lax regulation in the medical industry -- prompting many to be sceptical of domestically-produced pharmaceuticals.
Desperately searching for treatment for sick family members, Qiu, 22, told AFP she spent thousands on Covid medicines that never arrived, after contacting someone online who was claiming to represent Hong Kong-based Ghitai Pharmaceutical.
The person said they had access to stocks of Paxlovid -- a Beijing-approved Covid treatment developed by US drug giant Pfizer -- and could mail some from the semi-autonomous city into mainland China.
After being directed to a sleek "official" website, Qiu then forked out 12,000 yuan ($1,740) for six boxes of Paxlovid, according to payment records seen by AFP.
The pills, however, never came and the representative cut off contact, leaving her "hurt, helpless and extremely angry".
"It's disgusting behaviour," Qiu said. "Every second counts when you're trying to save somebody's life."
- Prices soar -
In a statement to AFP, Ghitai said it was aware of a fake version of its website that claimed to provide Covid medication, adding that instances of fraud had been reported to police.
"Ghitai has never offered medicines... for Covid-19, and entreats consumers to exercise caution to avoid fraud and financial losses," the company said.
Authorities in China have said they have begun shipping Paxlovid to some hospitals and community clinics, but the drug remains extremely difficult for many to obtain.
Multiple clinics in several cities -- including Beijing and mega-city Shanghai -- told AFP they were not currently offering the treatment and did not know when they could do so.
Limited stocks on e-commerce platforms have also rapidly sold out, leaving scalpers to cash in.
One seller contacted by AFP this week said they were charging 18,000 yuan ($2,610) for a single box -- around nine times the official price.
They claimed the medicine would be shipped from the southern city of Shenzhen, but said buyers would "have to wait" for delivery.
The seller did not say how they had sourced the pills, and stopped responding after an AFP journalist identified themselves.
- 'Despair and helplessness' -
China's public security ministry on Monday ordered a crackdown on "illegal and criminal activity involving the production and sale of counterfeit epidemic-related medicines and related items".
Despite those risks, the black market remains a common last resort for people like Xiao, whose elderly grandfather fell ill in December.
The business administrator, 25, was "utterly bewildered" when an online tout demanded 18,000 yuan for Paxlovid.
She could not afford it, and her desperation turned to "despair and helplessness" when her grandfather died days later.
"I just don't get how some people were able to get hold of the medicine," she said. "People like us can't even buy one box. How do they have so many?"
With authorised medications virtually out of reach, some are taking a chance on illegally imported generic alternatives.
Overseas drugs typically come at a fraction of the cost, but importers can face legal action for bringing in unregulated medications.
Indian variants of Paxlovid are cheaper, but still command hefty sums.
In an online chat this week, an AFP reporter encountered a person claiming to be an Indian pharmacist who was offering anti-Covid generics for as much as 1,500 yuan ($217) per box to dozens of prospective Chinese buyers.
They included a variant of Paxlovid sold under the brand name Paxista, and two generics for pharmaceutical giant Merck's treatment called Movfor and Molaz.
Beijing gave conditional emergency approval last week to Merck's antiviral -- sold internationally as Lagevrio -- for use on vulnerable adults with Covid.
A Shenzhen-based intermediary for the pharmacist said they saw "no moral quandary" in setting high prices for the potentially life-saving medication, adding that they were more concerned about legal problems.
In the chat room, doubts about the reliability of the generics plagued several users.
Said one woman: "I just don't know who to believe."
E.Rodriguez--AT